Zaldiar Effervescent

Leaflet accompanying the packaging: patient information

Warning! The leaflet should be kept. Information on the immediate packaging in a foreign language.

Zaldiar Effervescent (Zaldiar), 37.5 mg + 325 mg, effervescent tablets

Tramadol hydrochloride + Paracetamol
Zaldiar Effervescent and Zaldiar are different trade names for the same medicine.

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.

Table of contents of the leaflet

• 1. What is Zaldiar Effervescent and what is it used for
• 2. Important information before taking Zaldiar Effervescent
• 3. How to take Zaldiar Effervescent
• 4. Possible side effects
• 5. How to store Zaldiar Effervescent
• 6. Contents of the packaging and other information

1. What is Zaldiar Effervescent and what is it used for

Zaldiar Effervescent is a combination medicine containing two active substances with analgesic effects: tramadol hydrochloride and paracetamol.
The indication for the use of Zaldiar Effervescent is the symptomatic treatment of moderate to severe pain in patients for whom it is appropriate to use tramadol and paracetamol simultaneously.
The medicine is intended for use in adults and adolescents aged 12 and over.

2. Important information before taking Zaldiar Effervescent

When not to take Zaldiar Effervescent:

• if the patient is allergic to tramadol hydrochloride, paracetamol, or any of the other ingredients of this medicine (listed in section 6),
• in case of acute alcohol intoxication, sedatives, painkillers, or other psychotropic medicines (used to treat mental disorders),
• in case of concurrent use of MAO inhibitors (certain medicines used to treat depression or Parkinson's disease) and for 14 days after their discontinuation,
• in severe liver failure,
• in patients with epilepsy that is resistant to treatment,
• in pregnant or breastfeeding women.

Warnings and precautions

Before starting treatment with Zaldiar Effervescent, the patient should discuss it with their doctor or pharmacist.
Page 1 8

• in case of taking other medicines containing tramadol or paracetamol. Overdose of paracetamol can cause life-threatening liver damage in some patients.
• in case of liver damage or disease, with alcoholic liver disease without cirrhosis, jaundice, or liver and bile duct disease. This may be due to jaundice or liver and bile duct disease.
• in case of kidney disease.
• in case of respiratory disorders, such as asthma or other lung diseases.
• in case of epilepsy and a history of seizures or taking other medicines that lower the seizure threshold, especially: selective serotonin reuptake inhibitors, tricyclic antidepressants, neuroleptics, centrally and locally acting painkillers.
• in case of a recent head injury, shock, or severe headaches with vomiting.
• in case of dependence on any medicines, including painkillers, such as morphine.
• in case of taking other painkillers containing buprenorphine, nalbuphine, or pentazocine.
• if the patient has depression and is taking antidepressants, as some of them may interact with tramadol (see "Zaldiar Effervescent and other medicines"). After taking tramadol in combination with certain antidepressants or tramadol alone, there is a small risk of serotonin syndrome. If the patient experiences any symptoms of this severe syndrome, they should immediately consult a doctor (see section 4 "Possible side effects"). During treatment with Zaldiar Effervescent, the patient should immediately inform their doctor if they experience severe diseases, including severe kidney disorders or sepsis (when bacteria and their toxins are present in the blood, leading to organ damage) or malnutrition, chronic alcoholism, or if they are also taking flucloxacillin (an antibiotic). There have been reports of a severe disease called metabolic acidosis (a blood and fluid disorder) in patients who have taken paracetamol regularly for a long time or have taken paracetamol with flucloxacillin. Symptoms of metabolic acidosis may include: severe breathing difficulties, including rapid deep breathing, drowsiness, nausea, and vomiting.

In case of anesthesia, the patient should inform their doctor or dentist about the use of Zaldiar Effervescent.
Zaldiar Effervescent should not be used to treat opioid dependence, as it does not alleviate their withdrawal symptoms.
Tolerance, psychological dependence, and physical dependence on the medicine may develop, especially after long-term use.
Withdrawal symptoms similar to those after opioid withdrawal may occur even after taking therapeutic doses and during short-term treatment.
Sleep apnea
Zaldiar Effervescent may cause sleep apnea, such as sleep apnea (pauses in breathing during sleep) and hypoxemia (low oxygen levels in the blood). Symptoms may include pauses in breathing during sleep, nighttime awakenings due to shortness of breath, difficulty maintaining sleep, or excessive daytime sleepiness. If the patient or another person observes these symptoms, they should contact a doctor. The doctor may consider reducing the dose.
If the patient experiences any of the following symptoms while taking Zaldiar Effervescent, they should tell their doctor:
Excessive fatigue, loss of appetite, severe abdominal pain, nausea, vomiting, or low blood pressure.
This may indicate that the patient has adrenal insufficiency (low cortisol levels). If such symptoms occur, the patient should contact a doctor, who will decide whether the patient needs hormone replacement therapy.
Page 2 8
Tramadol is converted in the liver by an enzyme. In some people, there is a certain variation of this enzyme, which can have different effects. In some people, pain relief may not be sufficient, and in others, the risk of serious side effects may be higher.
The patient should stop taking the medicine and immediately contact a doctor if they experience any of the following side effects: slowed breathing or shallow breathing, confusion, drowsiness, pinpoint pupils, nausea, or vomiting, constipation, loss of appetite.
If any of these situations have occurred to the patient in the past or have occurred while taking Zaldiar Effervescent, they should inform their doctor. The doctor will decide whether to continue treatment with the medicine.

Zaldiar Effervescent and other medicines

The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.

Important: this medicine contains paracetamol and tramadol. The patient should tell their doctor about taking other medicines containing paracetamol or tramadol to avoid overdose of these medicines.

Contraindicatedis the concurrent use of Zaldiar Effervescent with MAO inhibitors and for 14 days after their discontinuation, see "When not to take Zaldiar Effervescent".
It is not recommended to take Zaldiar Effervescent concurrently with:

• carbamazepine (commonly used as an antiepileptic and also in certain types of pain, such as severe facial pain called trigeminal neuralgia).
• other opioid painkillers, such as buprenorphine, nalbuphine, or pentazocine, as their analgesic effect may be weakened.
• alcohol, including medicines containing alcohol. The patient should inform their doctor or pharmacist if they are taking:
• flucloxacillin (an antibiotic), due to the risk of a serious blood and fluid disorder (called metabolic acidosis), which requires emergency treatment (see section 2).

The risk of side effects increases if the patient takes:

Zaldiar Effervescent concurrently with:

• certain antidepressants, selective serotonin reuptake inhibitors, tricyclic antidepressants, and mirtazapine, as Zaldiar Effervescent may interact with them and cause serotonin syndrome (see section 4 "Possible side effects").
• other painkillers, such as morphine and codeine (as a cough suppressant), baclofen (a muscle relaxant), blood pressure-lowering medicines, and antihistamines, as they may increase the risk of central nervous system depression. If drowsiness or decreased attention occur, the patient should inform their doctor. Concurrent use of Zaldiar Effervescent and sedatives, such as benzodiazepines or derivatives, increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and may be life-threatening. Therefore, concurrent use of these medicines should only be considered when other treatment options are not possible. If the doctor has prescribed Zaldiar Effervescent together with sedatives, the doctor should limit the dose and duration of concurrent treatment. The patient should inform their doctor about all sedatives they are taking and strictly follow the doctor's dosage recommendations. It may be helpful to inform friends or relatives to be aware of the possibility of these subjective and objective symptoms. In case of such symptoms, the patient should contact a doctor.

Page 3 8

• medicines that may cause seizures, such as antidepressants or antipsychotics. The risk of seizures may increase if the patient takes Zaldiar Effervescent concurrently with these medicines. The doctor should inform the patient whether Zaldiar Effervescent is suitable for them.
• warfarin or phenprocoumon (for "thinning" the blood). The effect of these medicines may change, and bleeding may occur. Any prolonged or unexpected bleeding requires immediate consultation with a doctor. The patient should periodically have their prothrombin time checked. The effectiveness of Zaldiar Effervescent may change when taken concurrently with:
• metoclopramide, domperidone, or ondansetron (anti-emetic and anti-vomiting medicines),
• cholestyramine (a medicine used to lower cholesterol levels in the blood),
• ketoconazole or erythromycin (antibiotics).

The doctor will decide which medicines can be safely taken concurrently with Zaldiar Effervescent.

Zaldiar Effervescent with food, drink, and alcohol

Zaldiar Effervescent may cause drowsiness. Alcohol (including alcoholic beverages and some medicines) increases drowsiness. The patient should not drink alcohol while taking Zaldiar Effervescent.

Children and adolescents

Use in children with respiratory disorders

Zaldiar Effervescent should not be used in children with respiratory disorders, as tramadol toxicity symptoms may be more severe in them.

Pregnancy, breastfeeding, and fertility

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Tramadol is excreted into breast milk. Therefore, during breastfeeding, the patient should not take Zaldiar Effervescent more than once, or if they have taken Zaldiar Effervescent more than once, they should stop breastfeeding.
Zaldiar Effervescent should not be used during pregnancy and breastfeeding.
No studies have been conducted on the effect of the combination of tramadol and paracetamol on fertility.

Driving and using machines

Zaldiar Effervescent may cause drowsiness, which may affect the ability to drive and use machines. The patient should not drive or use machines while taking this medicine.
The medicine contains a colorant - orange yellow (E 110), which may cause allergic reactions.

This medicine contains 7.8 mmol (or 179.4 mg) of sodium per dose.

The patient should talk to their doctor or pharmacist if they need to take 2 or more effervescent tablets per day for a long time. This is especially important for a low-sodium diet.

One tablet contains 2.9 mg of potassium.

This medicine contains sulfites (a component of orange flavor)– the medicine may rarely cause severe hypersensitivity reactions and bronchospasm.

3. How to take Zaldiar Effervescent

Page 4 8
This medicine should always be taken as directed by the doctor. In case of doubts, the patient should consult their doctor or pharmacist.
Zaldiar Effervescent should be taken for the shortest possible time.
The medicine should not be taken in children under 12 years of age.
The dose should be adjusted according to the severity of the pain and the individual patient's response to treatment.
The patient should take the smallest effective dose for pain relief.
If the doctor has not recommended otherwise, the recommended dose of Zaldiar Effervescent is 2 effervescent tablets for adults and adolescents aged 12 and over.
If necessary, the doctor may recommend taking additional doses. Additional doses should not be taken more frequently than every 6 hours.

Do not take more than 8 effervescent tablets per day.

The patient should not take Zaldiar Effervescent more frequently than recommended by their doctor.
Elderly patients
In patients over 75 years of age, tramadol may be eliminated from the body more slowly. In these patients, the doctor may recommend prolonging the time interval between doses.
Patients with kidney or liver failure, or those undergoing dialysis
Zaldiar Effervescent should not be taken in case of severe liver or kidney failure.
In case of mild or moderate failure, the doctor may recommend prolonging the time interval between doses.

Method of administration

The tablets should be taken orally.
An effervescent tablet should be dissolved in a glass of water.
If the patient feels that the effect of Zaldiar Effervescent is too strong (drowsiness or breathing difficulties) or too weak (pain does not subside significantly), they should consult their doctor.

Taking a higher dose of Zaldiar Effervescent than recommended

In case of taking a higher dose of the medicine than recommended, even if the patient feels well, they should immediately consult their doctor or pharmacist. There is a risk of liver damage, whose symptoms may appear later.

Missing a dose of Zaldiar Effervescent

In case of missing a dose, the pain may return. The patient should not take a double dose to make up for the missed dose but should continue taking the medicine according to the established schedule.

Stopping treatment with Zaldiar Effervescent

The patient should not suddenly stop taking this medicine without their doctor's recommendation. If the patient wants to stop taking the medicine, they should discuss it with their doctor, especially if they have been taking it for a long time.
The doctor will advise when and how to stop taking the medicine; this may involve gradually reducing the dose to minimize the risk of side effects (withdrawal symptoms).
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Page 5 8

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common: occur in more than 1 in 10 patients

• nausea,
• dizziness, drowsiness. Common: may occur in up to 1 in 10 patients
• vomiting, digestive disorders (constipation, bloating, diarrhea), stomach pain, dry mouth,
• itching, excessive sweating,
• headache, tremors,
• confusion, sleep disorders, mood changes (anxiety, nervousness, abnormal euphoria). Uncommon: may occur in up to 1 in 100 patients
• increased heart rate or blood pressure, arrhythmias,
• difficulty urinating or pain,
• skin reactions (e.g., rash, hives),
• tingling, numbness, or a feeling of pins and needles in the limbs, ringing in the ears, involuntary muscle twitching,
• depression, nightmares, hallucinations, memory lapses,
• difficulty swallowing, blood in the stool (black stools),
• chills, hot flashes, chest pain,
• breathing difficulties,
• increased liver enzyme values.

Rare: may occur in up to 1 in 1000 patients

• seizures, difficulty coordinating movements,
• addiction, hallucinations,
• blurred vision, pinpoint pupils,
• speech disorders,
• dilated pupils,
• brief loss of consciousness (fainting).

Unknown: frequency cannot be estimated from the available data

• decreased blood sugar levels,
• hiccups,
• central sleep apnea syndrome (cases of SIADH and hyponatremia have been reported in the literature, although a causal relationship with tramadol has not been established).
• serotonin syndrome, whose symptoms may include changes in mental status (e.g., agitation, hallucinations, coma), as well as other symptoms, such as fever, rapid heart rate, unstable blood pressure, involuntary muscle contractions, muscle stiffness, lack of coordination, and (or) gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) (see section 2 "Important information before taking Zaldiar Effervescent"),
• a serious condition that can make the blood more acidic (called metabolic acidosis), in patients with severe disease taking paracetamol (see section 2).

The following side effects have been observed in patients taking only tramadol or only paracetamol. However, if they occur after taking Zaldiar Effervescent, the patient should tell their doctor:

• Fainting when standing up from a lying or sitting position, bradycardia (slow heart rate), collapse (fainting), changes in appetite, muscle weakness, slower or shallower breathing, changes in mood, changes in activity, changes in cognitive abilities, worsening of asthma.

Page 6 8

• In rare cases, the following have occurred: skin rash indicating an allergic reaction, which may manifest as sudden swelling of the face and neck, difficulty breathing, low blood pressure, and fainting. If the patient experiences any of these symptoms, they should stop taking the medicine and immediately consult a doctor. The patient should not restart taking the medicine.
• During treatment with paracetamol, very rare cases of severe skin reactions (rash with blisters all over the body, ulcers in the mouth, eyes, genitals, and skin, red spots on the torso, often with blisters in the center, large blisters bursting, skin peeling off in large patches, weakness, fever, and joint pain) have been reported. The patient should stop taking the medicine and immediately consult a doctor. The patient should not restart taking the medicine.

In rare cases, taking tramadol may cause dependence and difficulties with withdrawal.
In rare cases, patients taking tramadol for some time may experience malaise after sudden discontinuation. They may experience: restlessness, anxiety, nervousness, or tremors. Patients may be overactive, have sleep problems, and gastrointestinal disorders.
A very small number of patients may experience panic attacks, hallucinations, unusual sensations like itching, tingling, numbness, or a feeling of pins and needles. If any of these symptoms occur in the patient after stopping Zaldiar Effervescent, they should contact their doctor.
In exceptional cases, blood test results may show abnormalities, such as a low platelet count, which may lead to nosebleeds or bleeding gums.
Taking Zaldiar Effervescent with medicines used to "thin" the blood (e.g., phenprocoumon, warfarin) may increase the risk of bleeding. In case of any prolonged or unexpected bleeding, the patient should immediately consult a doctor.

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warszawa, Tel: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Zaldiar Effervescent

The medicine should be stored out of sight and reach of children.
Do not store above 25°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.

6. Contents of the packaging and other information

What Zaldiar Effervescent contains

• The active substances of the medicine are tramadol hydrochloride and paracetamol. One effervescent tablet contains 37.5 mg of tramadol hydrochloride and 325 mg of paracetamol.

Page 7 8

• The other ingredients of the medicine are: sodium citrate, citric acid, povidone K 30, sodium bicarbonate, macrogol 6000, colloidal silica anhydrous, magnesium stearate, orange flavor (maltodextrin (corn), modified starch (E 1450), natural and artificial flavors, sulfites), acesulfame potassium, sodium saccharin, orange yellow (E 110).

What Zaldiar Effervescent looks like and contents of the pack

The tablet is round, flat with beveled edges, mottled, white to light pink in color.
The tablets are packaged in soft aluminum foil blisters with a PET outer layer and a PE inner layer, in a cardboard box.
The single pack contains: 20 effervescent tablets (5x4), 28 effervescent tablets (7x4), 32 effervescent tablets (8x4), or 48 effervescent tablets (12x4).
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Spain, the country of export:

Grünenthal Pharma, S.A., Doctor Zamenhof, 36, 28027 Madrid, Spain

Manufacturer:

Grünenthal GmbH, Zieglerstrasse 6, D-52078 Aachen, Germany

Parallel importer:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź

Repackaged by:

Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
Spanish marketing authorization number: 662457.9

Parallel import authorization number: 22/24

Leaflet approval date: 16.07.2025

[Information about the trademark]
Page 8 8